Sutton R, Bourgeois I
Royal Brompton Hospital, London, U.K.
Eur Heart J. 1996 Apr;17(4):574-82. doi: 10.1093/oxfordjournals.eurheartj.a014911.
The benefits of dual (DDD) over single chamber pacing (VVI) have been demonstrated in haemodynamics, exercise capacity, quality of life and reduced complications in atrioventricular block and sick sinus syndrome. The literature was reviewed to provide complication rates for dual and VVI pacing. Cost calculations were based on United Kingdom 1991 prices. Over a 10-year period, a computer model calculated the incidence and prevalence of atrial fibrillation, stroke, permanent disability, heart failure and mortality in six patient categories: sick sinus syndrome paced VVI, sick sinus syndrome upgraded to DDD, sick sinus syndrome paced DDD from outset, atrioventricular block paced VVI and those upgraded to DDD and atrioventricular block paced initially DDD. Calculations were based on intention to treat. The 10 year survival with DDD vs VVI pacing was 71% vs 57% in sick sinus syndrome and 61% vs 51%, respectively, in atrioventricular block. In both indications the prevalence of heart failure in the 10 year survivors was 60% lower with DDD pacing. In sick sinus syndrome patients paced VVI, 36% had severe disability while only 8% experienced this with DDD pacing. For atrioventricular block the figures were, respectively, 22% vs 3%. The difference in 10 year cumulative cost between VVI and DDD is 13 times the purchase price of a VVI pulse generator for sick sinus syndrome and 7 times for atrioventricular block. In the third year after implantation the cumulative costs of DDD were lower than for VVI for both indications. Dual chamber pacing for both indications, sick sinus syndrome and atrioventricular block, is both clinically and cost effective.
双腔(DDD)起搏相较于单腔起搏(VVI),在血流动力学、运动能力、生活质量以及降低房室传导阻滞和病态窦房结综合征的并发症方面的优势已得到证实。本文回顾了相关文献,以提供双腔起搏和VVI起搏的并发症发生率。成本计算基于英国1991年的物价。在10年期间,计算机模型计算了六种患者类型中心房颤动、中风、永久性残疾、心力衰竭和死亡率的发生率及患病率,这六种患者类型分别为:VVI起搏的病态窦房结综合征、升级为DDD起搏的病态窦房结综合征、一开始就采用DDD起搏的病态窦房结综合征、VVI起搏的房室传导阻滞以及升级为DDD起搏的房室传导阻滞和一开始就采用DDD起搏的房室传导阻滞。计算基于意向性治疗。在病态窦房结综合征中,DDD起搏与VVI起搏的10年生存率分别为71%和57%;在房室传导阻滞中,分别为61%和51%。在这两种适应症中,10年存活者中DDD起搏的心力衰竭患病率比VVI起搏低60%。在VVI起搏的病态窦房结综合征患者中,36%有严重残疾,而DDD起搏时只有8%。对于房室传导阻滞,这一数字分别为22%和3%。VVI和DDD之间10年累计成本的差异,对于病态窦房结综合征来说是VVI脉冲发生器购买价格的13倍,对于房室传导阻滞来说是7倍。在植入后的第三年,两种适应症下DDD的累计成本均低于VVI。对于病态窦房结综合征和房室传导阻滞这两种适应症,双腔起搏在临床和成本效益方面均具有优势。